English Polski
Vol 18, No 2 (2023)
Case report
Published online: 2022-05-30

open access

Page views 2160
Article views/downloads 264
Get Citation

Connect on Social Media

Connect on Social Media

Complications of percutaneous coronary intervention in 70 years old patient with multivessel coronary artery disease and prostate cancer

Kinga Zujko1, Narcyza Żygieło1, Małgorzata Knapp1, Anna Lisowska1
Folia Cardiologica 2023;18(2):84-86.

Abstract

A 70-year-old man with chronic coronary artery disease (CAD), disseminated atherosclerosis, heart failure with mildly reduced ejection fraction, hypertension, diabetes mellitus type 2 and prostate cancer was admitted to the Department of Cardiology because of low effort tolerance for further cardiological assessment before chemotherapy of prostate cancer. Due to the progression of CAD in coronarography, he was consulted at the Heart Team meeting and classified for two-step percutaneous coronary intervention (PCI). After PCI of the left anterior descending artery, he had a myocardial infarction with the ejection fraction decreased from 43% to 28%.

Article available in PDF format

View PDF Download PDF file

References

  1. Bryer E, Stein E, Goldberg S. Multivessel coronary artery disease. Mayo Clin Proc Innov Qual Outcomes. 2020; 4(6): 638–641.
  2. Nelson-Veniard M, Thambo JB. Chemotherapy-induced cardiotoxicity: Incidence, diagnosis and prevention. Bull Cancer. 2015; 102(7–8): 622–626.
  3. Lefrak EA, Pitha J, Rosenheim S, et al. A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer. 1973; 32(2): 302–314, doi: 10.1002/1097-0142(197308)32:2<302::aid-cncr2820320205>3.0.co;2-2.
  4. Marchandise B, Schroeder E, Bosly A, et al. Early detection of doxorubicin cardiotoxicity: Interest of Doppler echocardiographic analysis of left ventricular filling dynamics. Am Heart J. 1989; 118(1): 92–98.
  5. Jain D, Aronow W. Cardiotoxicity of cancer chemotherapy in clinical practice. Hosp Pract. 2019; 47(1): 6–15.
  6. Opolski G, Krzakowski M, Szmit S, et al. Grupa Robocza Konsultantów Krajowych w Dziedzinie Kardiologii i Onkologii Klinicznej ds. opracowania rekomendacji postępowania kardiologicznego u chorych na raka piersi. Rekomendacje krajowego zespołu nadzoru kardiologicznego i onkologicznego dotyczące bezpieczeństwa kardiologicznego u chorych na raka piersi. Zapobieganie i postępowanie w powikłaniach sercowo-naczyniowych w raku piersi. Kardiol Pol. 2011; 69(5): 520–530.
  7. Suter TM, Procter M, van Veldhuisen DJ, et al. Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial. J Clin Oncol. 2007; 25(25): 3859–3865.
  8. Tripathy D, Seidman A, Keefe D, et al. Effect of cardiac dysfunction on treatment outcomes in women receiving trastuzumab for HER2-overexpressing metastatic breast cancer. Clin Breast Cancer. 2004; 5(4): 293–298.